Free Trial

Cardio Diagnostics Q3 2023 Earnings Report

Cardio Diagnostics logo
$0.36 +0.03 (+9.09%)
As of 04:00 PM Eastern

Cardio Diagnostics EPS Results

Actual EPS
-$0.17
Consensus EPS
-$0.39
Beat/Miss
Beat by +$0.22
One Year Ago EPS
N/A

Cardio Diagnostics Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cardio Diagnostics Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Remove Ads

Cardio Diagnostics Earnings Headlines

Cardio Diagnostics (CDIO) to Release Quarterly Earnings on Monday
A market crash is coming—here’s when
The stock market cycle I've used to identify the most likely day of the next market crash is the exact same indicator that helped me call the bear market of 2018... the bull market in 2020... the bear market in 2022... the roaring bull markets in 2023 and 2024... and more. I'm convinced it has helped me identify the next big crash too. We are at an important juncture in the markets. Knowing what to do in the months to come is critical.
Cardio Diagnostics files $50M mixed securities shelf
See More Cardio Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cardio Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardio Diagnostics and other key companies, straight to your email.

About Cardio Diagnostics

Cardio Diagnostics (NASDAQ:CDIO) develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

View Cardio Diagnostics Profile

More Earnings Resources from MarketBeat